BioSpace News Archive

Trident Brands Inc. (OTCQB: TDNT) today announced that their Brain Armor® brand of neuro-nutrition supplements has appointed Pamela Andrews as Managing Director.

Week 14 of Sermo’s COVID-19 Real Time Barometer survey revealed that 92 percent of physicians in the United States are recommending that patients get their annual flu shot as soon as possible in light of the COVID-19 pandemic

In August, Beijing Biocytogen Biotechnology Co., Ltd. (“Biocytogen”) announced acquisition of Eucure Biopharma, which established Biocytogen as a clinical stage company. Now, Biocytogen is plea

Award-winning Agilex Biolabs, the Asia-Pacific region’s leading bioanalytical laboratory for clinical trials, based in Australia, has developed the world’s most accurate cannabinoid assay.

Theralink Technologies (OTC: OBMP) (“Theralink” or the “Company”), formerly OncBioMune Pharmaceuticals, Inc. , a molecular profiling company specializing in patented, biomarker assay services that target multiple areas of oncology, today announced the completion of its previously announced corporate name change to Theralink Technolog

Servier, an independent international pharmaceutical company, has awarded the 2020 Servier Golden Ticket at MBC BioLabs to Telo Therapeutics, a biotechnology company focusing on working on s

A coalition of organizations representing millions of patients who live with serious, acute, and chronic conditions has released principles to guide policymakers seeking to ensure patients can continue to safely access appropriate telehealth services during and after the COVID-19 public health emergency.

Signify Health, a leading provider of technology-enabled healthcare solutions designed to keep people healthy and happy at home, and Ciox Health, a leader in health information management, today announced a strategic alliance to develop a master patient record for payers and risk-bearing health systems participating in value-based care models.

Verena at Bedford Falls, part of the True Connection Communities (“TCC”) family, announced today that the community has been treated with MicroShield 360’s two-step antimicrobial coating system that kills a broad spectrum of pathogens and viruses, including SARS CoV-2 (the specific coronavirus that causes COVID-19 disease), and protects from cross-contamination, odors, and mold between cleanings

- Study concludes that imlifidase leads to rapid clearance of anti-GBM antibodies, with two-thirds of patients achieving dialysis independence six months after treatment - Positive data demonstrates potential to increase renal survival in anti-GBM antibody disease and marks an important milestone for expansion of imlifidase outside transplantation [24-September-2020]